Market Newsdesk

Highlights Include:

• Elevated linear radon trends including a one-kilometer-long anomaly trending northeast
• Second anomaly detected in the northeast portion of the grid, both of which remain open along strike
• Survey results reinforce the property’s exploration potential
  

VANCOUVER, British Columbia, Aug. 27, 2025 (GLOBE NEWSWIRE) — Foremost Clean Energy Ltd. (NASDAQ: FMST) (CSE: FAT) (“Foremost” or the “Company”) is pleased to announce the results of its recently completed radon survey, at the Wolverine Uranium Property (“Wolverine”), located in the world-renowned Athabasca Basin region of northern Saskatchewan, approximately 15 kilometers southeast of the Cigar Lake Mine site (see Figure 1). The radon survey, previously announced on June 25, 2025, was conducted by RadonEx Ltd. consisting of both radon flux monitoring over land and a small radon-in-water component to test adjacent wetlands. A total of 893 data points were collected over the survey grid. The survey grid was designed to cover two potential faults which may explain the notable unconformity offset¹ observed on the property (see Figure 2).

Jason Barnard, President and CEO states “These survey results provide strong evidence that the interpreted structures at Wolverine are associated with elevated radon anomalies which may suggest the presence of subsurface uranium. This strengthens our confidence that the property has the right geological setting to host high-grade unconformity-style uranium mineralization. With these results in hand, our technical team will now integrate the radon data with historical geophysical and drill information to refine high-priority drill targets for future testing. We look forward to advancing Wolverine, which looks like another highly promising project to the ten-project portfolio we have optioned from Denison Mines. We are eager to advance our understanding of this site and systematically unlock any significant mineral potential.”

Radon Survey Results and Structural Interpretation

Radon surveying is geochemical approach which leverages the relationship between radon gas emissions and the presence of subsurface uranium. As uranium decays, it produces radon gas as one of its daughter products. Because radon is a gas, it can migrate toward the surface, particularly along faults and fractures, where it can be detected and measured.

Results from the radon flux monitoring identified elevated radon trends within the property, including a one-kilometer-long anomaly trending northeast and a second anomaly in the northeast portion of the grid, both of which remain open along strike (see Figure 3).

To better visualize survey results, Foremost has ranked all radon flux values relative to the highest value collected during the program. The maximum value is ranked “10”, with all other results scaled accordingly. This ranked dataset highlights a pronounced NNE-trending radon anomaly that closely coincides with an interpreted structural feature on the property (see Figure 3). While the radon trend closely parallels the structure, it is slightly offset, which is expected given that the structure is interpreted from magnetics reflecting basement rocks, whereas radon values are measured at surface. This correlation suggests that the structure may be fertile and represents a compelling target for future drill programs.

About the Wolverine Property

Wolverine is part of Foremost’s unique collaboration with Denison Mines Corp. (TSX: DML, NYSE American: DNN) and consists of three mineral claims totaling 12,444 acres (5,036 hectares). Historic work has been conducted on Wolverine by various companies including geophysical surveys and drilling programs. Previous exploration identified uranium mineralization, including drill hole WL10-01 that intersected 2,087 ppm U over 0.1 meters². Numerous airborne and ground-based geophysical surveys suggest a complex, structural architecture on the property. Drilling from 2011-2014 indicates up to 50m of unconformity displacement. The controlling fault is non-conductive and its precise location is uncertain.

Next Steps

Foremost intends to integrate the results with historical geochemical and geophysical data to refine high-priority drill targets, which could form the basis for future drill testing of the property.

Figure 1. Wolverine Property in Regional Context

Figure 2. Wolverine Property Compilation Map

Figure 3. Wolverine Property Radon Survey Results Map

Qualified Person

The technical content of this news release has been reviewed and approved by Cameron MacKay, P. Geo., Vice President of Exploration for Foremost Clean Energy Ltd., and a Qualified Person under National Instrument 43-101, who has prepared and reviewed the content of this press release.

A qualified person has not performed sufficient work or data verification to validate the historical results in accordance with National Instrument 43-101. Although the historical results may not be reliable, the Company nevertheless believes that they provide an indication of the property’s potential and are relevant for any future exploration program.

About
Foremost

Foremost Clean Energy Ltd. (NASDAQ: FMST) (CSE: FAT) (WKN: A3DCC8) is a rapidly growing North American uranium and lithium exploration company. The Company holds an option holds an option from Denison Mines Corp. (“Denison”) to earn up to a 70% interest in 10 prospective uranium properties (with the exception of the Hatchet Lake, where Foremost is able to earn up to 51%), spanning over 330,000 acres in the prolific, uranium-rich Athabasca Basin region of northern Saskatchewan. As the demand for carbon-free energy continues to accelerate, domestically mined uranium and lithium are poised for dynamic growth, playing an important role in the future of clean energy. Foremost’s uranium projects are at different stages of exploration, from grassroots to those with significant historical exploration and drill-ready targets. The Company’s mission is to make significant discoveries alongside and in collaboration with Denison through systematic and disciplined exploration programs.

Foremost also has a portfolio of lithium projects at varying stages of development, which are located across 55,000+ acres in Manitoba and Quebec. For further information, please visit the Company’s website at www.foremostcleanenergy.com.

Contact and Information

Company

Jason Barnard, President and CEO
+1 (604) 330-8067 
[email protected]

Follow us or contact us on social media:

X: @fmstcleanenergy
LinkedIn: https://www.linkedin.com/company/foremostcleanenergy  
Facebook: https://www.facebook.com/ForemostCleanEnergy

Forward-Looking Statements

Except for the statements of historical fact contained herein, the information presented in this news release and oral statements made from time to time by representatives of the Company are or may constitute “forward-looking statements” as such term is used in applicable United States and Canadian laws and including, without limitation, within the meaning of the Private Securities Litigation Reform Act of 1995, for which the Company claims the protection of the safe harbor for forward-looking statements. These statements relate to statements regarding expectations with respect to energy and uranium demand and the Company’s exploration plans and objectives. Any other statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions or future events or performance (often, but not always, using words or phrases such as “expects” or “does not expect,” “is expected,” “anticipates” or “does not anticipate,” “plans,” “estimates” or “intends,” or stating that certain actions, events or results “may,” “could,” “would,” “might” or “will” be taken, occur or be achieved) are not statements of historical fact and should be viewed as forward-looking statements. Such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such risks and other factors include, among others, the availability of capital to fund programs and the resulting dilution caused by the raising of capital through the sale of shares, continuity of agreements with third parties and satisfaction of the conditions to the option agreement with Denison, risks and uncertainties associated with the environment, delays in obtaining governmental approvals, permits or financing. Although the Company has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events or results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate as actual results and future events could differ materially from those anticipated in such statements. Although the Company believes that the expectations reflected in such forward-looking statements are based upon reasonable assumptions, it can give no assurance that its expectations will be achieved. Forward-looking information is subject to certain risks, trends and uncertainties that could cause actual results to differ materially from those projected. Many of these factors are beyond the Company’s ability to control or predict. Important factors that may cause actual results to differ materially and that could impact the Company and the statements contained in this news release can be found in the Company’s filings with the Securities and Exchange Commission. The Company assumes no obligation to update or supplement any forward-looking statements whether as a result of new information, future events or otherwise. Accordingly, readers should not place undue reliance on forward-looking statements contained in this news release and in any document referred to in this news release. This news release shall not constitute an offer to sell or the solicitation of an offer to buy securities. Please refer to the Company’s most recent filings under its profile on Sedar+ at www.sedarplus.ca and on Edgar at www.sec.gov for further information respecting the risks affecting the Company and its business.

The CSE has neither approved nor disapproves the contents of this news release and accepts no responsibility for the adequacy or accuracy hereof
.

---

¹ Unconformity Offset Interpreted from drillhole logs. See Saskatchewan Mineral Assessment Files 74H053, 74H15-0068 and 74H10-0071
² See Saskatchewan Mineral Assessment File 74H15-0068.

Photos accompanying this announcement are available at:

https://www.globenewswire.com/NewsRoom/AttachmentNg/58fd187f-43ae-4ebc-9fd8-de787e63d305

https://www.globenewswire.com/NewsRoom/AttachmentNg/0b10d290-4067-4bcf-a3ee-08716082df00

https://www.globenewswire.com/NewsRoom/AttachmentNg/744e3e1f-fd5c-4e9c-a348-07088c6ad545

MIAMI, Aug. 27, 2025 (GLOBE NEWSWIRE) — InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced plans to present at the upcoming H.C. Wainwright 27th Annual Global Investment Conference on Wednesday, September 10^th at 10:00am Eastern Time (ET).

A live audio webcast and replay of the presentation may be accessed on the “Investor Calendar” section of the company’s website at: https://inspiremd.com/investors/investor-calendar/

About InspireMD, Inc.

InspireMD seeks to utilize its proprietary MicroNet™ mesh technology to make its products the industry standard for carotid stenting by providing outstanding acute results and durable, stroke-free long-term outcomes. InspireMD’s common stock is quoted on Nasdaq under the ticker symbol NSPR. We routinely post information that may be important to investors on our website. For more information, please visit www.inspiremd.com.

Investor Contacts:

Webb Campbell
Gilmartin Group LLC
[email protected]
[email protected]

Addison, TX, Aug. 27, 2025 (GLOBE NEWSWIRE) — PatentVest, Inc., a leader in intellectual property strategy and prosecution, announces a strategic partnership with Docana, Inc., an emerging innovator in AI-powered enterprise knowledge extraction. This collaboration represents a shared commitment to advancing scalable innovation through the integration of robust IP frameworks and cutting-edge artificial intelligence.

As part of the partnership, PatentVest will provide strategic legal and IP consulting services to support the growth and protection of Docana’s technology portfolio. In return, Docana will grant PatentVest access to its next-generation AI platform, designed to streamline document analysis, automate reasoning, and accelerate enterprise decision-making.

Unlocking Value Through Complementary Capabilities

“Partnering with PatentVest gives us access to deep expertise in intellectual property that’s essential as we scale. Their strategic insight will ensure that our innovations in enterprise AI are protected and positioned for long-term success.” — Docana, Inc.

With decades of experience supporting innovation-driven companies across emerging technology sectors, PatentVest will help Docana develop a layered and future-ready intellectual property strategy—including patent protection, trade secrets management, and competitive positioning.

At the same time, Docana’s AI platform will enhance PatentVest’s internal knowledge workflows, offering a real-world example of how artificial intelligence can transform the delivery of IP strategy services.

“Docana represents the next wave of enterprise AI, and we’re thrilled to support their journey with strategic IP guidance. This partnership also gives us a unique opportunity to shape how AI can elevate the way IP strategy is built and delivered.” — Javier Chamorro, COO, PatentVest

About PatentVest

PatentVest, a division of MDB Capital Holdings (Nasdaq: MDBH), is the first integrated IP intelligence, strategy, and law firm designed to help visionary companies become technology leaders. By combining a proprietary database with a proven diligence process and expert analysis, PatentVest delivers actionable insights that help clients navigate complex IP landscapes and stay ahead of the curve. This report is powered by PatentVest’s proprietary IP intelligence platform.

About Docana

Docana is a deep tech company leveraging proprietary artificial intelligence to automate enterprise document intelligence and unlock knowledge at scale. Its platform combines natural language processing and workflow automation to accelerate complex decision-making in data-intensive environments.

For more information or inquiries, please contact [email protected].

SAN DIEGO, Aug. 27, 2025 (GLOBE NEWSWIRE) — LPL Financial Holdings Inc. (Nasdaq: LPLA), the parent corporation of LPL Financial LLC, today announced that First Horizon Bank, the banking subsidiary of First Horizon Corporation (NYSE: FHN), has transitioned support of the bank’s broker-dealer and investment advisory services program, First Horizon Advisors, Inc., to LPL and its institution services platform.

“This integration ushers in a new era of expanded capabilities for First Horizon Advisors,” said Martin de Laureal, executive vice president, Wealth Management and Private Banking, First Horizon Bank. “With LPL’s advanced platform, we’re elevating how we serve clients, delivering even more personalized advice and setting the stage for meaningful growth and stronger relationships.”

“Our relationship with First Horizon is built on a shared commitment to providing outstanding advisor support,” said Christopher Cassidy, SVP, head of Institution Business Development, LPL Financial. “With the full strength of LPL’s integrated platform, First Horizon Advisors is well-positioned to drive deeper value and lasting impact for clients.”

LPL and First Horizon Bank announced the agreement in April 2025. In August 2025, approximately $12B of brokerage and advisory assets onboarded to LPL. The remaining direct custodied assets are expected to onboard over the next several months.

About First Horizon Corporation


First Horizon Corporation (NYSE: FHN), with $82.1 billion in assets as of June 30, 2025, is a leading regional financial services company, dedicated to helping our clients, communities and associates unlock their full potential with capital and counsel. Headquartered in Memphis, TN, the banking subsidiary First Horizon Bank operates in 12 states concentrated in the southern U.S. The Company and its subsidiaries offer commercial, private banking, consumer, small business, wealth and trust management, retail brokerage, capital markets, fixed income, and mortgage banking services. First Horizon has been recognized as one of the nation’s best employers by Fortune and Forbes magazines and a Top 10 Most Reputable U.S. Bank. More information is available at www.FirstHorizon.com.

About LPL Financial


LPL Financial Holdings Inc. (Nasdaq: LPLA) is among the fastest growing wealth management firms in the U.S. As a leader in the financial advisor-mediated marketplace, LPL supports over 29,000 financial advisors and the wealth management practices of approximately 1,100 financial institutions, servicing and custodying approximately $1.9 trillion in brokerage and advisory assets on behalf of approximately 7 million Americans. The firm provides a wide range of advisor affiliation models, investment solutions, fintech tools and practice management services, ensuring that advisors and institutions have the flexibility to choose the business model, services, and technology resources they need to run thriving businesses. For further information about LPL, please visit www.lpl.com.

Securities and advisory services offered through LPL Financial LLC (“LPL Financial”), a registered investment advisor and broker-dealer, member FINRA/SIPC.

First Horizon Bank, First Horizon Corp., First Horizon Advisors, Inc., LPL Financial Holdings Inc. and LPL Financial are separate entities.

Throughout this communication, the terms “financial advisors” and “advisors” are used to refer to registered representatives and/or investment advisor representatives affiliated with LPL Financial.

We routinely disclose information that may be important to shareholders in the “Investor Relations” or “Press Releases” section of our website.

*Value approximated based on asset and holding details as of August 26, 2025, provided to LPL Financial by First Horizon Bank.

Forward-Looking Statements 
Certain of the statements included in this release, such as those regarding the expected onboarding of assets associated with the strategic relationship and the benefits anticipated of the relationship, constitute forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Words such as “expects,” “believes,” “anticipates,” “plans,” “assumes,” “estimates,” “projects,” “intends,” “should,” “will,” “shall” or variations of such words are generally part of forward-looking statements. Forward-looking statements are made based on current expectations and beliefs concerning future developments and their potential effects upon First Horizon, LPL or both. In particular, no assurance can be provided that the assets reported as serviced by financial advisors affiliated with First Horizon will translate into assets serviced by LPL or that the benefits that are expected to accrue to First Horizon, LPL and First Horizon-affiliated advisors as a result of the strategic relationship will materialize. These forward-looking statements are not a guarantee of future performance and involve risks and uncertainties, including economic, legislative, regulatory, competitive and other factors, and there are certain important factors that could cause actual results or the timing of events to differ, possibly materially, from expectations or estimates expressed or implied in such forward-looking statements. Important factors that could cause or contribute to such differences include: difficulties or delays of LPL in transitioning advisors affiliated with First Horizon, or in onboarding First Horizon’s clients and businesses or transitioning their assets from First Horizon’s current third-party custodian to LPL; the inability of LPL to sustain revenue and earnings growth or to fully realize revenue or expense synergies or the other expected benefits of the transaction, which depend in part on LPL’s success in onboarding assets currently served by First Horizon’s advisors; disruptions to First Horizon’s or LPL’s businesses due to transaction-related uncertainty or other factors making it more difficult to maintain relationships with financial advisors and clients, employees, other business partners or governmental entities; the inability of LPL or First Horizon to implement onboarding plans; the choice by clients of First Horizon-affiliated advisors not to open brokerage and/or advisory accounts at LPL; changes in general economic and financial market conditions, including retail investor sentiment; fluctuations in the value of assets under custody; and the effects of competition in the financial services industry, including competitors’ success in recruiting First Horizon-affiliated advisors. Certain additional important factors that could cause actual results or the timing of events to differ, possibly materially, from expectations or estimates expressed or implied in such forward-looking statements can be found in the “Risk Factors” and “Special Note Regarding Forward-Looking Statements” sections included in LPL’s most recent Annual Report on Form 10-K. Except as required by law, First Horizon and LPL do not undertake to update any particular forward-looking statement included in this document as a result of developments occurring after the date of this press release.

Contacts 

LPL Media Relations 
[email protected] 

LPL Investor Relations 
[email protected] 

Tracking #784487

PRINCETON, N.J., Aug. 27, 2025 (GLOBE NEWSWIRE) — MISTRAS Group, a global leader in technology-enabled industrial asset integrity and testing solutions, is proud to announce its partnership with Bechtel on the Hanford Vit Plant Project. MISTRAS will deliver a comprehensive range of non-destructive testing (NDT) services to support this critical project, which plays a key role in the U.S. Department of Energy’s mission to treat and stabilize nuclear waste at the Hanford Site in Washington State.

The Hanford Vit Plant Project involves the construction of a state-of-the-art facility designed to process and vitrify high-level radioactive waste, converting it into a stable, glass form for long-term storage. This project is part of the United States’ ongoing efforts to mitigate the risks posed by nuclear waste and ensure the safety of surrounding communities and ecosystems. The Hanford Vit Plant is one of the most challenging and complex environmental remediation projects in the world.

MISTRAS will support this project by providing expert NDT services to ensure the quality, safety, and integrity of critical systems and structures. The services will include Radiography (RT), Magnetic Particle Testing (MT), Liquid Penetrant Testing (PT), Positive Material Identification (PMI), Ultrasonic Thickness Testing (UT), and Leak Testing. All services will be performed by MISTRAS’ certified technicians, ensuring high-quality, code-compliant results with thorough documentation that adheres to industry standards and regulatory requirements.

Gennaro D’Alterio, Chief Commercial Officer at MISTRAS, shared his enthusiasm about the partnership, stating:

“We are thrilled to collaborate on such a significant project. The Hanford Vit Plant is a critical piece of infrastructure for the safe treatment of nuclear waste, and we are proud to contribute our expertise in non-destructive testing to support its success. This project also represents a key milestone in executing MISTRAS’ diversification strategy, as we continue to expand our capabilities and serve new markets while delivering the highest standards of quality, safety, and regulatory compliance.”

The Hanford Vit Plant Project, once completed, will be capable of processing millions of gallons of highly radioactive liquid waste, a key environmental cleanup effort at one of the largest nuclear waste sites in the world. This facility will contribute significantly to the long-term health and safety of local communities and the environment, ensuring the safe containment and disposal of radioactive waste for future generations.

About MISTRAS Group
MISTRAS Group, Inc. (NYSE: MG) is a global leader in technology-enabled industrial asset integrity and testing solutions, serving critical industries including oil & gas, aerospace & defense, power & utilities, manufacturing, and civil infrastructure. The company provides a diversified portfolio of products and services, ranging from advanced non-destructive testing and pipeline inspections to real-time condition monitoring, maintenance planning, and specialized engineering, powered by a proprietary management software suite that centralizes integrity data for predictive analytics and benchmark analysis. With a long-standing track record of innovation and deep industry expertise, MISTRAS helps clients reduce risk, extend asset life, and optimize operational performance. Learn more at www.mistrasgroup.com.

Contact:

Theresa Feraren
Senior Vice President & Chief Marketing Officer
MISTRAS Group, Inc.
[email protected]

SAN DIEGO, Aug. 27, 2025 (GLOBE NEWSWIRE) — Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect Biopharma, Connect or the Company), a clinical-stage biopharmaceutical company focused on transforming care for the treatment of inflammatory diseases, today announced that Company management will participate in the following upcoming conferences:

Cantor Global Healthcare Conference 2025

Format: Fireside Chat
Date: Wednesday, September 3^rd, 2025
Time: 3:20 p.m. ET
Webcast Link: Register Here

H.C. Wainwright 27

^th

Annual Global Investment Conference

Format: Fireside Chat
Date: Monday, September 8^th, 2025
Time: 9:30 a.m. ET
Webcast Link: Register Here

Live webcasts of the presentations may be accessed via the Investors section of the Connect website at investors.connectbiopharma.com. Archived replays of both events will be available on the website for approximately 90 days following the conference.

About Connect Biopharma

Connect Biopharma is a clinical-stage biopharmaceutical company dedicated to transforming care for asthma and COPD. Headquartered in San Diego, California, the Company is advancing rademikibart, a next-generation, potentially best-in-class antibody designed to target IL-4Rα. The Company is currently conducting global clinical studies of rademikibart for the treatment of acute exacerbations of asthma and COPD, areas with significant unmet need. Connect also has an exclusive license and collaboration agreement for rademikibart with Simcere in China.

For more information visit www.connectbiopharma.com.

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended (the “Act”). Forward-looking statements are statements that are not of historical fact and include, without limitation, statements regarding future events, our future financial condition, results of operations, business strategy and plans, prospective products (as well as their potential to achieve a differentiated, competitive, or favorable benefit or profile or trend, including on safety, tolerability, improvement, maintenance, clinical response, dosing, efficacy and/or convenience), planned or expected product approval applications or approvals, anticipated milestones, expected data readouts and enrollments, research and development plans and costs, potential future partnerships, expectations about existing partnerships, timing and likelihood of success, objectives of management for future operations, future results of anticipated product development efforts, and adequacy of existing cash and potential partnership funding to fund operations and capital expenditure requirements, as well as statements regarding industry trends. These statements are based on management’s current expectations of future events only as of the date of this press release and are inherently subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond our control, including, among other things: the ability of our clinical trials to demonstrate safety and efficacy of our product candidates and other positive results; whether we will need expanded or additional trials in order to obtain regulatory approval for our product candidates; our ability to obtain and maintain regulatory approval of our product candidates; existing regulations and regulatory developments in the U.S., the PRC, Europe and other jurisdictions; the ability of our current cash and investments position to support planned operations; our plans and ability to obtain, maintain, protect and enforce our intellectual property rights and our proprietary technologies, including extensions of existing patent terms where available; our continued reliance on third parties to conduct additional clinical trials of our product candidates, and for the manufacture of our product candidates for preclinical studies and clinical trials; and the degree of market acceptance of our product candidates, if approved, by physicians, patients, healthcare payors and others in the medical community.

Words such as “aim,” “anticipate,” “believe,” “could,” “expect,” “feel,” “goal,” “intend,” “may,” “optimistic,” “plan,” “potential,” “promising,” “will,” and similar expressions are intended to identify forward-looking statements, though not all forward-looking statements necessarily contain these identifying words. The inclusion of forward-looking statements should not be regarded as a representation by Connect Biopharma that any of its expectations, projections or plans will be achieved. Actual results may differ materially due to the risks and uncertainties inherent in our business and other risks described in our filings with the U.S. Securities and Exchange Commission (the “SEC”). Further information regarding these and other risks is included under the heading “Risk Factors” in our annual and periodic reports filed with the SEC. These forward-looking statements should not be taken as forecasts or promises nor should they be taken as implying any indication, assurance or guarantee that the assumptions on which such forward-looking statements have been made are correct or exhaustive or, in the case of the assumptions, fully stated in this presentation. Drug development and commercialization involve a high degree of risk, and only a small number of research and development programs result in commercialization of a product. Results in early-stage clinical trials may not be indicative of full results or results from later stage or larger scale clinical trials and do not ensure regulatory approval. You are cautioned not to place undue reliance on the scientific data presented or these forward-looking statements, which speak only as of the date of this presentation. Except as required by law, Connect Biopharma undertakes no obligation to publicly update any forward-looking statements, whether because of new information, future events or otherwise. Connect Biopharma claims the protection of the safe harbor for forward-looking statements contained in the Act for all forward-looking statements.

This press release discusses our product candidate, rademikibart, which is under clinical investigation and has not yet been approved for marketing by the U.S. Food and Drug Administration, the National Medical Products Administration, or by any other regulatory agency. No representation is made as to the safety or effectiveness of rademikibart for the uses for which it is being studied. The trademarks included herein are the property of the owners thereof and are used for reference purposes only.

Investor Relations Contact:

Alex Lobo
Precision AQ
[email protected]
(212) 698-8802

Media Contact:

Ignacio Guerrero-Ros, Ph.D., or David Schull
Russo Partners, LLC
[email protected]
[email protected]
(858) 717-2310 or (646) 942-5604

August 27, 2025 

Next-generation 2D and 3D imaging and intelligent automation empower clinicians to make faster, more confident decisions in cardiac care

Amsterdam, the Netherlands –
Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced the release of Transcend Plus, the next generation its EPIQ CVx and Affiniti CVx cardiovascular ultrasound systems. Transcend Plus delivers major advancements in image quality and artificial intelligence (AI), including newly FDA-cleared 2D and 3D image quality enhancements and a growing suite of AI-enabled clinical applications – all designed to meet the growing challenges of cardiac care delivery. With increased patient volume, rising clinical complexity, and persistent staffing shortages, Transcend Plus is designed to help cardiology teams work smarter, not harder – offering fast, reproducible results with uncompromising image quality and decision-making support.

“Transcend Plus represents a bold leap forward in the evolution of echocardiography, reinforcing our commitment to continuous innovation, empowering clinicians with AI-driven tools that enhance confidence, accelerate decision-making, and elevate care at every stage of the cardiac journey,” said David Handler, Business Leader, Cardiology Ultrasound at Philips. “Transcend Plus is more than an advancement – it’s a clear statement of Philips’ leadership in cardiovascular ultrasound. Building on the momentum of our original Transcend launch, Transcend Plus brings the full power of AI integration to the forefront, giving clinicians the confidence, speed, and precision they need to lead in cardiac care – today and into the future.”

Industry-leading image quality now enhanced

Transcend Plus visibly improves sharpness, contrast, and detail in 2D and 3D imaging, featuring the latest FDA-cleared enhancements for EPIQ CVx and Affiniti CVx. These upgrades support superior visualization of cardiac anatomy and function, enabling diagnostic confidence even in the most complex or technically challenging cases. The update also introduces the new 2D Auto EF Advanced feature, expanding AI capabilities for contrast images – essential for accurately assessing cardiac function.

“Artificial intelligence is a tool, not a threat, and I always maintain that human plus AI is going to be better than human alone or AI alone – the 3D Auto CFQ and 3D Auto TV AI applications are examples of this, taking manual, time-consuming processes and automating these measurements in a fast, easy and reproducible way,” said Akhil Narang, MD, Director, Echocardiography Laboratory and Associate Professor of Medicine, Division of Cardiology at the Feinberg School of Medicine, Northwestern University and Bluhm Cardiovascular Institute.

26 FDA-cleared AI applications, now fully integrated

Philips now offers 26 FDA-cleared cardiovascular ultrasound AI applications – the most in the industry – fully integrated into Transcend Plus for both EPIQ and Affiniti CVx systems. Among the latest enhancements to receive FDA 510(k) clearance are 2D Auto EF and 2D Auto EF Advanced. These advanced tools are designed to streamline clinical workflows and improve diagnostic accuracy across a range of care settings, from the echo lab through the hospital to outpatient clinics, pre-assessment, and long-term follow-up. With these integrated AI applications, clinicians can assess patients more quickly, consistently, and confidently across the entire care continuum.

Why left ventricular function assessment matters

Left ventricular (LV) function assessment is one of the most critical applications in cardiac imaging, playing a central role in diagnosing and managing a wide range of cardiac conditions. Transcend Plus directly supports this need by delivering fast, reproducible results that help cardiologists quickly and definitively evaluate LV function consistently across different patients and over time. Automated tools minimize operator variability, ensuring more reliable and standardized measurements, especially vital in high-volume or high-pressure clinical environments. In addition, Transcend Plus offers robust support for both contrast and non-contrast imaging. The 2D Auto EF feature enables accurate assessments even when contrast agents cannot be used, such as in patients with renal impairment. Building on this, 2D Auto EF Advanced adds AI-powered quantification capabilities for both contrast and non-contrast studies, broadening clinical applicability and enhancing measurement reliability in patients with poor image quality or challenging acoustic windows. These capabilities combine to deliver a more confident, efficient approach to cardiac care.

Clinical confidence, anywhere, anytime

Transcend Plus empowers clinicians to make fast, confident decisions across every cardiac care setting – whether in the echo lab, interventional suite, or during routine outpatient assessments. By delivering sharper imaging and intelligent automation, it enables more informed care, streamlines workflows, and helps providers manage growing patient volumes without compromising diagnostic quality or clinician well-being. Transcend Plus delivers three core benefits: enhanced image quality for clearer visualization of cardiac anatomy and improved diagnostic precision; advanced AI integration, with 26 FDA-cleared applications that automate and accelerate routine tasks; and faster, more actionable insights that reduce delays and support timely, evidence-based clinical decisions throughout the care journey.

Philips Ultrasound systems installed around the world perform an estimated 1.33 billion diagnostic and interventional procedures each year, supporting diagnosis and treatment for 654 million unique patients annually. Transcend Plus will be demonstrated live at the European Society of Cardiology 2025 Congress (ESC) in Madrid (Aug. 29 – Sept. 1) and the American Society of Echocardiography annual meeting (ASE) in Nashville (Sept. 5 – Sept. 7), offering hands-on clinical insight into how these innovations are transforming cardiac ultrasound. Visit Philips Cardiovascular Ultrasound for more information.

For further information, please contact:

Kathy O’Reilly
Philips Global External Relations
Tel.: +1 978-221-8919
E-mail: [email protected]

Joost Maltha
Philips Global External Relations
Tel.: +31 6 1055816
E-mail: [email protected]

About Royal Philips

Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people’s health and well-being through meaningful innovation. Philips’ patient- and people-centric innovation leverages advanced technology and deep clinical and consumer insights to deliver personal health solutions for consumers and professional health solutions for healthcare providers and their patients in the hospital and the home.

Headquartered in the Netherlands, the company is a leader in diagnostic imaging, ultrasound, image-guided therapy, monitoring and enterprise informatics, as well as in personal health. Philips generated 2024 sales of EUR 18 billion and employs approximately 67,300 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter.

Attachments

• Transcend Plus Ultrasound system in use
• EPIQ CVx system clinical view
• Mini 3D TEE transducer clinical view

BOCA RATON, FL, Aug. 27, 2025 (GLOBE NEWSWIRE) — DeFi Development Corp. (Nasdaq: DFDV) (the “Company”), the first U.S. public company built to accumulate Solana’s native token, SOL, today announced it will ring the Nasdaq Closing Bell this Friday, August 29, 2025, at 4:00 p.m. Eastern Time at Nasdaq MarketSite in New York City.

The bell ringing will mark a significant milestone in DFDV’s journey, while also serving as a moment to bring together the broader Solana community and highlight the ecosystem’s rapid growth. For DFDV, the event symbolizes both the celebration of its progress and raising awareness of Solana’s innovation on one of the world’s biggest financial stages – in many ways, a moment of “taking Solana public.”

The public can watch the ceremony live here: Nasdaq Closing Bell Ceremony Livestream

Those interested in attending the bell ringing in person may contact [email protected]. Attendance is limited and subject to approval.

About DeFi Development Corp.

DeFi Development Corp. (Nasdaq: DFDV) has adopted a treasury policy under which the principal holding in its treasury reserve is allocated to Solana (SOL). Through this strategy, the Company provides investors with direct economic exposure to SOL, while also actively participating in the growth of the Solana ecosystem. In addition to holding and staking SOL, DeFi Development Corp. operates its own validator infrastructure, generating staking rewards and fees from delegated stake. The Company is also engaged across decentralized finance (DeFi) opportunities and continues to explore innovative ways to support and benefit from Solana’s expanding application layer.

The Company is an AI-powered online platform that connects the commercial real estate industry by providing data and software subscriptions, as well as value-add services, to multifamily and commercial property professionals, as the Company connects the increasingly complex ecosystem that stakeholders have to manage.

The Company currently serves more than one million web users annually, including multifamily and commercial property owners and developers applying for billions of dollars of debt financing per year, professional service providers, and thousands of multifamily and commercial property lenders, including more than 10% of the banks in America, credit unions, real estate investment trusts (“REITs”), debt funds, Fannie Mae® and Freddie Mac® multifamily lenders, FHA multifamily lenders, commercial mortgage-backed securities (“CMBS”) lenders, Small Business Administration (“SBA”) lenders, and more. The Company’s data and software offerings are generally offered on a subscription basis as software as a service (“SaaS”).

Forward-Looking Statements

This release contains “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: “anticipate,” “intend,” “plan,” “believe,” “project,” “estimate,” “expect,” strategy,” “future,” “likely,” “may,”, “should,” “will” and similar references to future periods. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on the Company’s current beliefs, expectations, and assumptions regarding the future of its business, future plans and strategies, projections, anticipated events and trends, the economy, and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks, and changes in circumstances that are difficult to predict and many of which are outside of the Company’s control. The Company’s actual results and financial condition may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the following: (i) fluctuations in the market price of SOL and any associated impairment charges that the Company may incur as a result of a decrease in the market price of SOL below the value at which the Company’s SOL are carried on its balance sheet; (ii) volatility in our stock price, including due to future issuances of common stock and securities convertible into common stock; (iii) the effect of and uncertainties related the ongoing volatility in interest rates; (iv) our ability to achieve and maintain profitability in the future; (v) the impact on our business of the regulatory environment and complexities with compliance related to such environment including changes in securities laws or other laws or regulations; (vi) changes in the accounting treatment relating to the Company’s SOL holdings; (vii) our ability to respond to general economic conditions; (vii) our ability to manage our growth effectively and our expectations regarding the development and expansion of our business; (ix) our ability to access sources of capital, including debt financing and other sources of capital to finance operations and growth and (x) other risks and uncertainties more fully in the section captioned “Risk Factors” in the Company’s most recent Annual Report on Form 10-K and other reports we file with the SEC. As a result of these matters, changes in facts, assumptions not being realized, or other circumstances, the Company’s actual results may differ materially from the expected results discussed in the forward-looking statements contained in this press release. Forward-looking statements contained in this announcement are made as of this date, and the Company undertakes no duty to update such information except as required under applicable law.

Investor Contact:

[email protected]

Media Contact:

Prosek Partners
[email protected]

CHICAGO, Aug. 27, 2025 (GLOBE NEWSWIRE) — Guaranteed Rate Affinity, a leading mortgage provider offering unparalleled lending services through its partnership with Coldwell Banker, today announced the promotion of Jay Crowder to Divisional Manager, East Region. A respected leader within Guaranteed Rate Affinity since its inception in 2017, Crowder most recently served as a Regional President for the company. With over 30 years of experience in the mortgage industry, including 25 years in joint venture partnerships, he has a proven track record of recruiting top-performing talent.

In his new role, Crowder will lead strategic initiatives aimed at scaling production and expanding the sales force across Guaranteed Rate Affinity’s eastern market. His focus will include attracting best-in-class loan officers, enhancing team performance, and reinforcing a culture of excellence, collaboration, and client-first service.

“I’m excited to step into this expanded leadership role at Guaranteed Rate Affinity,” said Crowder. “We have an outstanding team, an incredible platform, and the opportunity to accelerate our momentum by empowering our people, deepening our partnerships, and delivering exceptional results for clients.”

Throughout his career, Crowder has consistently led high-performing teams, driven substantial production growth, and established strategic partnerships that have fueled long-term success. His deep expertise in joint ventures and passion for talent development are expected to further enhance the division’s performance and culture.

“Jay has been a pillar within Guaranteed Rate Affinity, and he’s only going to strengthen the Eastern region through his commitment to bringing on the best-of-the-best loan officers,” said Scott Throneberry, Executive Vice President of National Sales at Guaranteed Rate Affinity. “He reflects the culture and values we hold as a company, and we’re confident he’s only going to continue to improve the East with his leadership.”

About Guaranteed Rate Affinity

Guaranteed Rate Affinity is a joint venture between Guaranteed Rate, Inc. and Anywhere Integrated Services (NYSE: HOUS), which owns some of the industry’s most recognized and respected real estate brands. The innovative JV has funded over $100 billion in loans since its inception. Guaranteed Rate Affinity originates and markets its mortgage lending services to Anywhere’s real estate, brokerage, and relocation subsidiaries.

Guaranteed Rate Affinity provides unmatched support to Anywhere brokers coast-to-coast, ensuring their customers receive fast pre-approvals, appraisals, and loan closings, creating the ability for buyers to move quickly and confidently when purchasing homes in today’s competitive market. The company also provides the same services to the public and other real estate brokerage and relocation companies across the country—helping employers improve their employees’ relocation experience by prioritizing customer service, digital mortgage ease, and competitive rates.

Guaranteed Rate owns a controlling 50.1% stake in Guaranteed Rate Affinity, and Anywhere owns 49.9%. Visit grarate.com for more information.

Press Contact

[email protected]